专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019113318A1 PORTABLE MICROBIAL LOAD DETECTION 审中-公开
公开(公告)号：WO2019113318A1
公开(公告)日：2019-06-13
申请号：PCT/US2018/064251
申请日：2018-12-06
申请人： PINNACLE BIO, LLC
发明人： MADHIWALA, Aatish , PATEL, Yogi A. , MEHTA, Nilesh
IPC分类号： C12N7/00 , C12Q1/10
CPC分类号： G01N27/3274 , C12Q1/06 , G01N27/3272 , G01N27/3273 , G01N33/54366 , G01N33/66 , G01N33/9486 , G01N2800/26
摘要： Portable microbial load detection is disclosed. For example a test strip includes a calibration well with first, second, and third calibration traces and a sample well with first, second, and third test traces. A reader is configured to detect a connection with the test strip. A drive signal is applied to the test strip. A first voltage of the second calibration trace is measured indicating a reagent has been added to the calibration well. A second voltage of the third calibration trace is measured over a calibration time period and then used to calibrate the reader. An addition of a test sample in the sample well based is detected. A third voltage of the third test trace is measured over a test time period. A concentration of the compound in the test sample is calculated and used to report a diagnosis state.

2. 发明申请

WO2017139382A1 COMBINATION OF ADJUVANT DRUGS ESKETAMINE AND BRIMONIDINE FOR MEDICAL TREATMENTS 审中-公开
标题翻译：辅助药物ESKETAMINE和BRIMONIDINE联合用于医疗治疗
公开(公告)号：WO2017139382A1
公开(公告)日：2017-08-17
申请号：PCT/US2017/017022
申请日：2017-02-08
申请人： THE TEXAS A&M UNIVERSITY SYSTEM , POTTER, David E. , SCHAPIRO (HOOK), Michelle A.
发明人： POTTER, David E. , SCHAPIRO (HOOK), Michelle A.
IPC分类号： A61K45/06 , A61K31/135
CPC分类号： A61K31/135 , A61K9/0019 , A61K9/1652 , A61K31/498 , G01N33/9486 , A61K2300/00
摘要： The invention disclosed herein generally relates to compositions and methods related to a combination of adjuvant drugs for medical treatments. The present invention relates to combining the adjuvant drugs esketamine and brimonidine to treat medical conditions such as pain, depression and hearing loss.
摘要翻译：本文公开的发明总体上涉及与用于医学治疗的辅助药物的组合相关的组合物和方法。本发明涉及将佐剂药物艾氯胺酮和溴莫尼定组合以治疗诸如疼痛，抑郁症和听力丧失的医学病症。

3. 发明申请

WO2009151091A1 アルツハイマー病の検査方法审中-公开
标题翻译：检测阿尔茨海默病的方法
公开(公告)号：WO2009151091A1
公开(公告)日：2009-12-17
申请号：PCT/JP2009/060655
申请日：2009-06-11
申请人：エーザイ・アール・アンド・ディー・マネジメント株式会社 , キンタンミン , 小田吉哉 , 浅井直樹
发明人：キン　タン　ミン , 小田　吉哉 , 浅井　直樹
IPC分类号： G01N30/88 , G01N27/447 , G01N27/62 , G01N33/53
CPC分类号： G01N33/9453 , G01N30/72 , G01N33/9486 , G01N2800/2821 , Y10T436/174614
摘要：（１）リドカインが投与された被験者に由来する脳脊髄液中のリドカイン又はその代謝物の量を測定する測定工程と、（２）測定された量に基いて、被験者がアルツハイマー病であるか否かを判定する判定工程とを含む、アルツハイマー病の検査方法。
摘要翻译：公开了一种检查阿尔茨海默病发生的方法。该方法包括以下步骤（1）和（2）：（1）测量从利多卡因给药的受试者收集的脑脊髓液中的利多卡因或代谢的产物的量的测量步骤; 和（2）基于测量的量确定受试者是否患有阿尔茨海默氏病的确定步骤。

4. 发明申请

WO2009077593A1 ENDOGENOUS MORPHINE OR A NATURALLY OCCURING METABOLITE THEREOF AS A MARKER FOR INFECTION 审中-公开
标题翻译：内源性吗啡或作为感染标记的天然成分代谢物
公开(公告)号：WO2009077593A1
公开(公告)日：2009-06-25
申请号：PCT/EP2008/067907
申请日：2008-12-18
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , JUSTUS-LIEBIG UNIVERSITÄT , GOUMON, Yannick , AUNIS, Dominique , METZ-BOUTIGUE, Marie-Hélène , SCHNEIDER, Francis , WELTERS, Ingeborg
发明人： GOUMON, Yannick , AUNIS, Dominique , METZ-BOUTIGUE, Marie-Hélène , SCHNEIDER, Francis , WELTERS, Ingeborg
IPC分类号： G01N33/94
CPC分类号： G01N33/9486 , G01N2800/26
摘要： The invention relates to a method for detecting infection in a patient comprising measuring the concentration of endogenous morphine or a naturally occurring metabolite thereof in a biological sample obtained from said patient.
摘要翻译：本发明涉及一种用于检测患者感染的方法，包括测量从所述患者获得的生物样品中内源吗啡或其天然存在的代谢物的浓度。

5. 发明申请

WO2009036168A2 DEVICES AND METHODS FOR THE COLLECTION AND DETECTION OF SUBSTANCES 审中-公开
标题翻译：用于收集和检测物质的装置和方法
公开(公告)号：WO2009036168A2
公开(公告)日：2009-03-19
申请号：PCT/US2008076010
申请日：2008-09-11
申请人： UNIV FLORIDA , GOLD MARK S , MARTIN DAVID M , GOLD STEVEN T , GOLDBERGER BRUCE A
发明人： GOLD MARK S , MARTIN DAVID M , GOLD STEVEN T , GOLDBERGER BRUCE A
IPC分类号： G01N33/48 , B01L3/00 , C12M1/34
CPC分类号： G01N33/948 , A61B10/0045 , A61B10/0096 , B01L3/5029 , B01L3/5457 , B01L2200/0621 , B01L2300/021 , B01L2300/025 , B01L2300/0645 , B01L2300/0663 , B01L2300/0832 , B01L2300/0861 , B01L2400/0644 , B01L2400/0683 , G01N33/54386 , G01N33/9486 , Y10T436/145555
摘要： The present invention is a single self-contained device for collecting, transferring, extracting, and testing for the presence of a target analyte in a sample obtained from a surface by swabbing, solid materials (pills, capsules, unknown powders), air samples and biological and non-biological fluids. The device includes a swab, a retention well including eluent fluid, and analysis technologies which can include but are not limited to lateral flow testing analysis. The major improvement is the invention of rinsing the swab with proprietary elution fluid prior to testing thereby not compromising the chemistry and allowing for a wide variety of applications under extremely hot or cold field conditions. Also, the device is in one self-contained unit instead of having a separate water dropper or spray. Moreover, the shape of the device is similar to a magic marker so it is more substantial than any drug tester on the market, as well in certain embodiments it can have grips resembling a gun and in certain embodiments can even emit sounds or smells when a surface is wiped or a positive test is attained.
摘要翻译：本发明是用于收集，转移，提取和测试通过擦拭从表面获得的样品中存在目标分析物的单个自含装置，固体材料（药丸，胶囊，未知粉末），空气样品和生物和非生物流体。该装置包括拭子，包括洗脱液的保留孔以及可以包括但不限于侧流测试分析的分析技术。主要改进是发明在测试之前用专有洗脱液冲洗棉签，从而不损害化学性质并允许在极端炎热或寒冷的现场条件下进行各种各样的应用。此外，该设备是在一个独立的单位，而不是有一个单独的滴水器或喷雾。此外，该装置的形状类似于魔术标记器，因此它比市场上的任何药物测试器更具实质性，并且在某些实施例中，它可以具有类似于枪的握把，并且在某些实施例中甚至可以在发出声音或气味时发出声音或气味表面擦拭或获得正面测试。

6. 发明申请

WO2009020677A2 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING 审中-公开
标题翻译：抑制G蛋白信号传导的组合物和方法
公开(公告)号：WO2009020677A2
公开(公告)日：2009-02-12
申请号：PCT/US2008061757
申请日：2008-04-28
申请人： UNIV ROCHESTER , SMRCKA ALAN V , BLAXALL BURNS C , BIDLACK JEAN M
发明人： SMRCKA ALAN V , BLAXALL BURNS C , BIDLACK JEAN M
IPC分类号： G01N33/53
CPC分类号： G01N33/74 , A61K31/122 , A61K31/4709 , A61K31/498 , G01N33/564 , G01N33/6893 , G01N33/9486 , G01N2333/726 , G01N2500/04 , G01N2800/32 , G01N2800/325
摘要： Disclosed are compositions and methods for treating diseases associated with G protein ß? subunit acitivity.
摘要翻译：公开了用于治疗与G蛋白β有关的疾病的组合物和方法。亚基活性。

7. 发明申请

WO2007109324A2 POTENT AND SELECTIVE NAV 1.7 SODIUM CHANNEL BLOCKERS 审中-公开
标题翻译： POTENT和SELECTIVE NAV 1.7 SODIUM CHANNEL BLOCKERS
公开(公告)号：WO2007109324A2
公开(公告)日：2007-09-27
申请号：PCT/US2007/007025
申请日：2007-03-21
申请人： XENON PHARMACEUTICALS, INC. , FRASER, Robert, A. , SHERRINGTON, Robin , MACDONALD, Marcia, L. , SAMUELS, Mark , NEWMAN, Scott , FU, Jian-Min , KAMBOJ, Rajender
发明人： FRASER, Robert, A. , SHERRINGTON, Robin , MACDONALD, Marcia, L. , SAMUELS, Mark , NEWMAN, Scott , FU, Jian-Min , KAMBOJ, Rajender
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12N15/1138 , C12N2310/14 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , G01N33/5088 , G01N33/574 , G01N33/6872 , G01N33/9486 , G01N2500/04 , G01N2800/2842
摘要： The present invention relates to the discovery that mutations in Nav1.7 are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the Nav1.7 gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for Nav1.7, and are useful in the treatment of pain and other Nav1.7-mediated disorders. The invention discloses potent and selective small molecule inhibitors of Nay1.7 and also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
摘要翻译：本发明涉及Nav1.7突变是人类先天性疼痛无力（CIP）的原因的发现。本发明还涉及使用Nav1.7基因及其表达产物的方法，用于筛选和鉴定对Nav1.7有选择性的治疗剂，包括小有机化合物，并且可用于治疗疼痛和其他Nav1 .7介导的疾病。本发明公开了Nay1.7的有效和选择性的小分子抑制剂，并且还涉及使用这些化合物来治疗或改善此类疾病的方法。

8. 发明申请

WO2004019882A3 METHODS OF SCREENING FOR COMPOUNDS THAT MODULATE TAFIa ACTIVITY, COMPOUNDS, AND METHODS OF USING THE COMPOUNDS 审中-公开
标题翻译：筛选化合物的方法，该方法是调节TAFIA活性，化合物和使用该化合物的方法
公开(公告)号：WO2004019882A3
公开(公告)日：2006-04-13
申请号：PCT/US0327070
申请日：2003-08-29
申请人： AMERICAN DIAGNOSTICA INC , QUEBEPHARMA RECH INC
发明人： GRENNFIELD ROBERT S , AN SEONG SOO A , TRIFONOV LATCHEZAR , VAUGEOIS JEAN , SLEMON CLAIRE
IPC分类号： A61K31/60 , C12Q1/00 , C12Q1/56 , G01N33/573 , G01N33/68 , G01N33/86 , G01N33/94 , A61K38/28
CPC分类号： C12Q1/37 , A61K31/60 , C12Q1/56 , G01N33/573 , G01N33/6893 , G01N33/86 , G01N33/9486 , G01N2500/00
摘要： Provided are methods of screening compounds for any aspirin-related activity other than TAFI inhibition, and also for non-inhibition of TAFI. Compounds identified by the screening methods can be used to treat, prevent or manage in a patient pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder. Also provided is a method of evaluating test compounds for TAFI inhibitory activity wherein the TAFI inhibitory activity of these test compounds is compared to the TAFI inhibitory activity of aspirin or its derivatives or metabolites. Further provided is a method of treating, preventing or managing in a patient, a hemorrhagic or thrombotic disease or disorder with high dose aspirin or aspirin derivatives or metabolites. Also contemplated is a method of treating, preventing or managing in a patient, pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder comprising administering aspirin or a derivative thereof or any other therapeutic having at least one desired therapeutic or prophylactic activity of aspirin to a patient in need thereof and administering to the patient a factor that promotes TAFIa activity,
摘要翻译：提供了筛选化合物除了TAFI抑制以外的任何阿司匹林相关活性的方法，以及用于非抑制TAFI的方法。通过筛选方法鉴定的化合物可用于治疗，预防或控制患者疼痛，发烧，结肠癌，胰腺癌或炎症，血小板聚集，纤维蛋白溶解或出血性疾病或病症。还提供了评价试验化合物对TAFI抑制活性的方法，其中将这些试验化合物的TAFI抑制活性与阿司匹林或其衍生物或代谢物的TAFI抑制活性进行比较。还提供了一种治疗，预防或控制患者出血性或血栓性疾病或病症的方法，其中高剂量阿司匹林或阿司匹林衍生物或代谢物。还考虑了治疗，预防或控制患者疼痛，发烧，结肠癌，胰腺癌或炎症，血小板聚集，纤维蛋白溶解或出血性疾病或病症的方法，包括给予阿司匹林或其衍生物或任何其它治疗剂对有需要的患者的阿司匹林的至少一种期望的治疗或预防活性，并向患者施用促进TAFIa活性的因子，

9. 发明申请

WO2005105093A2 METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION 审中-公开
标题翻译：在其行政管理期间研究μ-阿片受体激动剂的副作用的方法
公开(公告)号：WO2005105093A2
公开(公告)日：2005-11-10
申请号：PCT/US2004/027669
申请日：2004-08-25
申请人： DUKE UNIVERSITY , BOHN, Laura, M. , WALKER, Julia, K., L. , LEFKOWITZ, Robert, J. , CARON, Marc, G.
发明人： BOHN, Laura, M. , WALKER, Julia, K., L. , LEFKOWITZ, Robert, J. , CARON, Marc, G.
IPC分类号： A61K31/485
CPC分类号： A61K31/485 , C12Q1/485 , G01N33/9486 , G01N2500/10
摘要： The present invention provides methods for decreasing the side effects of µ opioid receptor agonists and methods for screening compounds for activity in reducing the side effects of µ opioid receptor agonists.
摘要翻译：本发明提供了降低μ阿片受体激动剂的副作用的方法和用于筛选化合物用于降低μ阿片受体激动剂的副作用的活性的方法。

10. 发明申请

WO2005015203A2 DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH G PROTEIN-COUPLED OPIOID RECEPTOR MU 1 (OPRM1) 审中-公开
标题翻译：与G蛋白偶联的阿片受体MU 1（OPRM1）相关的疾病的诊断和治疗
公开(公告)号：WO2005015203A2
公开(公告)日：2005-02-17
申请号：PCT/EP2004/008344
申请日：2004-07-26
申请人： BAYER HEALTHCARE AG , GOLZ, Stefan , BRÜGGEMEIER, Ulf , GEERTS, Andreas
发明人： GOLZ, Stefan , BRÜGGEMEIER, Ulf , GEERTS, Andreas
IPC分类号： G01N33/48
CPC分类号： G01N33/6896 , G01N33/9486 , G01N2500/00
摘要： The invention provides a human OPRM1 which is associated with the neurological disorders, reproduction disorders, endocrinological disorders and gastro-enterological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of neurological disorders, reproduction disorders, endocrinological disorders and gastroenterological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of OPRM1 as well as pharmaceutical compositions comprising such compounds.
摘要翻译：本发明提供了与神经系统疾病，繁殖障碍，内分泌障碍和胃肠疾病有关的人类OPRM1。本发明还提供了用于鉴定可用于治疗或预防神经障碍，繁殖障碍，内分泌障碍和胃肠病学障碍的化合物的测定。本发明还涉及结合和/或活化或抑制OPRM1的活性的化合物以及包含这些化合物的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式